206 related articles for article (PubMed ID: 2752713)
41. The effect of varying ratios of ticarcillin to clavulanic acid against gentamicin-resistant and gentamicin-sensitive Enterobacteriaceae.
Wheat PF; Spencer RC
J Antimicrob Chemother; 1984 Aug; 14(2):195-6. PubMed ID: 6568225
[No Abstract] [Full Text] [Related]
42. Reassessment of susceptibility test interpretive criteria for ticarcillin and ticarcillin-clavulanic acid.
Fuchs PC; Jones RN; Barry AL
J Clin Microbiol; 1989 Nov; 27(11):2475-81. PubMed ID: 2808671
[TBL] [Abstract][Full Text] [Related]
43. Clinical trial of the efficacy and safety of ticarcillin and clavulanic acid.
Roselle GA; Bode R; Hamilton B; Bibler M; Sullivan R; Douce R; Staneck JL; Bullock WE
Antimicrob Agents Chemother; 1985 Mar; 27(3):291-6. PubMed ID: 3888101
[TBL] [Abstract][Full Text] [Related]
44. In vitro activity of amoxycillin plus clavulanic acid and ticarcillin plus clavulanic acid compared with that of other antibiotics against anaerobic bacteria.
Pierard D; De Meyer A; Rosseel P; Glupczynski Y; Struelens MJ; Delmee M; Pattyn SR; Verschraegen G; Melin P; Lauwers S
Acta Clin Belg; 1989; 44(4):228-36. PubMed ID: 2618522
[TBL] [Abstract][Full Text] [Related]
45. Activity of ticarcillin/clavulanate and piperacillin/tazobactam (YTR 830; CL-298,741) against clinical isolates and against mutants derepressed for class I beta-lactamase.
Knapp CC; Sierra-Madero J; Washington JA
Diagn Microbiol Infect Dis; 1989; 12(6):511-5. PubMed ID: 2560423
[TBL] [Abstract][Full Text] [Related]
46. Bactericidal effects of amoxycillin/clavulanic acid and ticarcillin/clavulanic acid in in-vitro kinetic models.
White AR; Stokes DH; Slocombe B; Sutherland R
J Antimicrob Chemother; 1985 Jan; 15 Suppl A():227-32. PubMed ID: 3980328
[TBL] [Abstract][Full Text] [Related]
47. Augmentation effect of clavulanic acid with penicillin, cephalothin and ticarcillin against Bacteroides fragilis.
Bansal MB; Chuah SK; Oryema-Lalobo M; Thadepalli H
Chemotherapy; 1985; 31(3):173-7. PubMed ID: 3996086
[TBL] [Abstract][Full Text] [Related]
48. Susceptibilities of 200 penicillin-susceptible and -resistant pneumococci to piperacillin, piperacillin-tazobactam, ticarcillin, ticarcillin-clavulanate, ampicillin, ampicillin-sulbactam, ceftazidime, and ceftriaxone.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Dec; 38(12):2905-7. PubMed ID: 7695281
[TBL] [Abstract][Full Text] [Related]
49. Sensitivity of clinical bacterial isolates to Timentin (ticarcillin/clavulanic acid).
Villiger JW
N Z Med J; 1986 Nov; 99(814):914. PubMed ID: 3492692
[No Abstract] [Full Text] [Related]
50. [In vitro study of the effects of a ticarcillin-clavulanic acid combination on Pseudomonas aeruginosa as a function of resistant phenotypes].
Thabaut A; Meyran M
Pathol Biol (Paris); 1985 May; 33(5):408-11. PubMed ID: 3929218
[TBL] [Abstract][Full Text] [Related]
51. The activity of ticarcillin in combination with clavulanic acid against Bacteroides species: an in-vitro comparison with other antibiotics.
de Barbeyrac B; Quentin C; Bébéar C
J Antimicrob Chemother; 1986 May; 17 Suppl C():35-9. PubMed ID: 3636337
[TBL] [Abstract][Full Text] [Related]
52. [Changes of antimicrobial resistance among nonfermenting gram-negative bacilli isolated from intensive care units from 1994 to 2001 in China].
Wang H; Chen MJ;
Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):385-90. PubMed ID: 12820914
[TBL] [Abstract][Full Text] [Related]
53. [Clinical evaluation of a ticarcillin-clavulanic acid combination in severe infections in adults].
Lacut JY; Quentin C; Cardoso-Mendes I; Dupon M
Pathol Biol (Paris); 1985 Jun; 33(5 Pt 2):591-5. PubMed ID: 3937132
[TBL] [Abstract][Full Text] [Related]
54. Comparative in vitro activity of azlocillin, ampicillin, mezlocillin, piperacillin, and ticarcillin, alone and in combination with an aminoglycoside.
White GW; Malow JB; Zimelis VM; Pahlavanzadeh H; Panwalker AP; Jackson GG
Antimicrob Agents Chemother; 1979 Apr; 15(4):540-3. PubMed ID: 111616
[TBL] [Abstract][Full Text] [Related]
55. Susceptibility of 114 isolates of the Bacteroides fragilis group to imipenem and eight other antimicrobial agents.
Downes J; Andrew JH
Pathology; 1988 Jul; 20(3):260-3. PubMed ID: 3205597
[TBL] [Abstract][Full Text] [Related]
56. Resistance rates to commonly used antimicrobials among pathogens of both bacteremic and non-bacteremic community-acquired urinary tract infection.
Lau SM; Peng MY; Chang FY
J Microbiol Immunol Infect; 2004 Jun; 37(3):185-91. PubMed ID: 15221039
[TBL] [Abstract][Full Text] [Related]
57. In vitro susceptibility of piperacillin v timentin and ticarcillin.
Bremner DA
N Z Med J; 1987 May; 100(823):299-300. PubMed ID: 3138579
[No Abstract] [Full Text] [Related]
58. The antibacterial activity of ticarcillin/clavulanic acid (BRL28500) against ticarcillin-resistant bacteria.
Kasai T; Nishino T; Kazuno Y; Tanino T
J Antibiot (Tokyo); 1986 Oct; 39(10):1450-60. PubMed ID: 3536827
[TBL] [Abstract][Full Text] [Related]
59. Comparative in vitro activity of ticarcillin, piperacillin, azlocillin and mezlocillin.
Chattopadhyay B; Hall I; Curnow SR
Curr Med Res Opin; 1983; 8(8):577-81. PubMed ID: 6653135
[TBL] [Abstract][Full Text] [Related]
60. [Clinical evaluation of timentin in intensive care].
Gérard A; Dureux JB; Canton P; May T; Schmit JL
Pathol Biol (Paris); 1986 May; 34(5):448-50. PubMed ID: 3534719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
